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Abstract
Cerebral venous thrombosis (CVT) is a less common cause of stroke that is an often 
under recognized entity in clinical practice. The goal of this chapter will be to provide 
clinicians with the knowledge to succinctly recognize the various presentations of CVT, 
emphasizing rapid diagnosis and the potential treatments necessary to produce optimal 
clinical outcomes. Detailed descriptions of the relevant anatomy and associated clinical 
syndromes will be discussed. Detailed sections regarding CVT epidemiology, patho-
physiology, etiology, diagnosis and treatment will be provided. Prognosis and long-term 
follow-up will also be discussed. Relevant literature will be cited and clinical trials across 
the spectrum of CVT will be highlighted.
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1. Introduction
Cerebral venous thrombosis (CVT) is a less common cause of stroke that is often under rec-
ognized in clinical practice. CVT accounts for 0.5–1% of strokes that has a preponderance to 
occur in women [1, 2]. The goal of this chapter is to provide clinicians with the knowledge and 
ability to recognize and treat CVT early in its time course leading to the best clinical outcomes.
2. Anatomy and associated clinical syndromes
The cerebral venous system is a network of superficial sinuses and deeper cortical veins that 
drain the superficial surfaces of both cerebral hemispheres and the deeper brain structures 
ultimately returning blood back to the heart via the internal jugular veins. The cerebral venous 
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system is divided into a superficial system (superior sagittal sinus, inferior sagittal sinus, cor-
tical veins) and a deep system (transverse sinus, straight sinus, sigmoid sinus, deeper cortical 
veins). The flow patterns and anatomy can be seen in in Figures 1 and 2.
The superficial cortical veins adhering to the arachnoid layer are thin walled and have no 
valves [3]. Typical cerebral venous flow starts with the superficial cortical veins draining into 
the superior/inferior sagittal sinus or straight sinus draining into the confluence of sinuses (also 
known as torcula or torcular herophili) to the transverse sinuses, sigmoid sinuses, and then 
internal jugular veins. The superior sagittal sinus drains the superior-lateral cerebral hemi-
spheric surfaces bilaterally. The diploic, meningeal and emissary veins drain into the supe-
rior sagittal sinus. This is of clinical importance in scalp and CSF infections as prothrombotic 
venous drainage into the superior sagittal sinus can induce thrombus formation within that 
structure. The inferior sagittal sinus drains the bilateral medial cerebral hemispheres as well as 
the falx cerebri. The inferior sagittal sinus joins with the great vein of Galen to form the straight 
sinus. The great vein of Galen is formed by the internal cerebral vein (formed by thalamostriate 
vein, septal vein and choroid vein) and basal vein of Rosenthal (anterior/middle cerebral vein 
and striate vein) which drain the basal ganglia and deep white matter bilaterally. The lateral 
sinuses (transverse and sigmoid sinuses) receive drainage directly from the posterior cerebral 
hemisphere, brainstem and cerebellum bilaterally. Of clinical importance, the anatomical posi-
tioning of these lateral sinuses near the mastoid air cells increases their susceptibility to throm-
bosis formation in the setting of ear infections such as chronic otitis media and mastoiditis [4].
Two unique parts of the venous sinus drainage system are the anastomotic veins and the bilat-
eral cavernous sinus. The superior anastomotic vein of Trolard connects the superior sagittal 
sinus and the superficial vein of Sylvius. The inferior anastomotic vein of Labbe connects the 
superficial middle cerebral vein and transverse sinus. The cavernous sinus receives drainage 
Figure 1. Cerebral venous anatomy.
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from the orbits, inferior frontal lobe, inferior parietal lobe and the face in the nasal region. Given 
that cranial nerves CNIII, CN IV, CN V-1, CN V-2 and CN VI pass through the cavernous sinus 
this becomes an important clinical localization point in the setting of facial and nasal infections.
Much of neurology involves pattern recognition in the setting of clinical findings and syn-
dromes. Clinical syndromes of the venous system are less well stereotyped than the more 
commonly seen and appreciated arterial stroke syndromes. Cerebral cortical veins often have 
a common presentation of focal seizure activity correlating with the specific region of the cor-
tex involved. Thrombosis involving the deep venous system leads to mental status changes 
and can progress to coma when the bilateral thalami are involved. Notably, thrombosis 
involving the deeper venous system generally results in a more rapid deterioration compared 
to the superficial system. Clinically, thrombosis in the superior sagittal sinus syndrome can 
present quite variably, but the classic syndrome includes bilateral motor deficits, neurobehav-
ioral issues related to frontal lobe injury, and seizure activity related to hemispheric cortical 
involvement. Other findings can include scalp and/or face edema, and dilated scalp veins 
based on the lack of venous flow into the sagittal sinus [5]. Thrombosis in the transverse 
venous sinus typically results in parietal lobe deficits with patients presenting with either 
aphasia or neglect depending on hemispheric dominance. Accompanying symptoms often 
include headaches, ear and/or mastoid pain. The visual pathways can also be affected in a 
lateral sinus thrombosis syndrome thus resulting in hemianopia secondary to occipital lobe 
involvement. Cavernous sinus thrombosis typically presents with diplopia, proptosis, head-
ache and orbital pain, or some combination of these, with the examiner eliciting cranial nerve 
palsies involving CN-III, CN-IV, CN-V1, CN-V2, CN VI.
Figure 2. Cerebral venous anatomy on magnetic resonance venogram (MRV).
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3. Epidemiology
CVT, in absolute terms, is an uncommon diagnosis occurring in 5 per 1 million adults every 
year [1]. In all, CVT accounts for 0.5–1% of all strokes [6]. In the International Study on 
Cerebral Vein and Dural Sinus Thrombosis (ISCVT) trial, which evaluated 624 patients in 
24 countries, subjects had a median age of 37 years old (78% cases <50 years old) with 74% 
of enrollees being female, illustrating that CVT is generally a disease of young women [3]. 
The overall incidence of CVT is 1.32 per 100,000 person-years [7]. CVT occurs in women at a 
higher rate than men, with the women aged 31–50 years harboring the greatest risk with an 
incidence of 2.78 per 100,000 person-years [7, 8]. Among the young stroke population, CVT 
accounts for approximately 5% of cases [9].
The incidence of CVT in the Canadian Pediatric Ischemic Stroke Registry (CRISR) was 6.7 
per 1 million [10]. A majority (54%) of the children were younger than 1 year old with 45% 
below the age of 1 month. This patient population will be further discussed in the following 
section.
4. Pathophysiology
The potential causes for CVT are numerous, but the underlying reason is the coagulation bal-
ance is tipped towards a pro-thrombotic state. There are numerous predisposing factors that 
contribute to the formation of CVT. Examples include medical problems such as thrombo-
philias, infections and inflammatory states (e.g., autoimmune diseases), transient physiologi-
cal states including dehydration and pregnancy, medications especially oral contraceptives 
(OCPs), smoking, and head trauma [11, 12].
The main data on epidemiology of CVT comes from the International Study on Cerebral Vein 
and Dural Sinus Thrombosis (ISCVT). An ISCVT study demonstrated that more than 44% of 
the subjects were identified to have more than one cause to their CVT [13]. In that study the 
most common contributing factor was OCP use (54%) followed by thrombophilia (34.1%), 
puerperium (14%), infection (12%), malignancy (7.4%) and pregnancy (6%). These contribut-
ing factors give credence to the predilection for women in child bearing years. Specifically, 
OCP use, pregnancy and puerperium risks are exclusive to that subset of patients. An esti-
mated 2% of strokes during pregnancy can be attributed to CVT [14]. The puerperium period 
is the first 6–8 weeks after childbirth, and it is in that period where the risk of all venous 
thromboembolic events is increased, with an overall frequency of CVT estimated to be 12 per 
100,000 delivers [15, 16]. Although there is limited evidence, factors that have been associ-
ated with puerperium CVT include hyperhomocysteinemia, advanced maternal age, cesar-
ean delivery, maternal hypertension, infections and excessive vomiting during pregnancy 
[17, 18]. In developing and underdeveloped countries, postpartum strokes are relatively 
common with contributing risk factors including poor antenatal and postpartum care, home 
deliveries, anemia, and dehydration. During pregnancy itself, the highest incidence world-
wide is during the 3rd trimester [19].
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The proposed mechanism for the observed young female preponderance is that hormonal 
factors create a prothrombotic state. The reason many authors cite this to be true is that the 
incidence of CVT among elderly and children is sex-independent [10, 20]. More evidence sup-
porting hormonal contribution to the pathophysiology is the association between CVT and 
ovarian hyperstimulation syndrome [21]. The relative risk of CVT among OCP users was as 
high as 15.9 in one study [22]. A meta-analysis that examined 17 CVT studies calculated an 
OR 5.59 increased risk of CVT with OCP use [23]. The effect is synergistic when OCP use is 
combined with a hereditary prothrombotic factors including factor V Leiden or prothrom-
bin G20210A mutation, with the latter demonstrating an OR of 149.3 in one study [24, 25]. 
Pregnancy and OCP use, absent genetic conditions, are thought to be transient and thus gen-
erally not thought to carry a higher risk of recurrence.
Numerous studies have been dedicated to exploring the association between genetic hyper-
coagulability and CVT risk. A meta-analysis that reviewed 26 case–control studies including 
1183 CVT cases and 5189 controls, demonstrated the two gene mutations that most clearly 
associated with CVT risk were Factor V Leiden/G1691A (OR 2.40 [1.75–3.30; p-value 0.00001) 
and prothrombin gene mutation (OR 5.48 [3.88–7.74]; p-value 0.00001) [26]. In the same study, 
they performed an iterative analysis which showed a statistically significant association with 
methylene tetrahydrofolate reductase/C677T (OR 2.30 [1.20–4.42; p-value 0.02). Similar asso-
ciations were described in systematic reviews that showed statistically significant increases 
in odds ratio (OR) for prothrombin gene mutation (9.27 [5.85–1467]), Factor V Leiden (3.38 
[2.27–5.05]) and hyperhomocysteinemia (4.07 [2.54–6.52]) [27]. In ISCVT 22% of the patients 
had a genetic hypercoagulable state [13]. In decreasing order of frequency, the identified 
genes were G20210A prothrombin mutation, Factor V Leiden, anticardiolipin/antiphospho-
lipid antibodies, protein C deficiency, protein S deficiency and antithrombin III deficiency 
[3, 15, 18, 24, 27–31].
Another acquired hypercoagulable state that is common in the setting of CVT is malignancy. 
The mechanism by which malignancy causes hypercoagulability is varied. Authors have 
suggested that potential mechanisms may include tumor invasion of venous sinuses, com-
pression of dural venous sinuses, an imbalance in systemic inflammatory mediators, chemo-
therapy, and targeted hormone therapy (i.e., tamoxifen for breast cancer treatment) [32–35]. 
The associated malignancies represented were primary CNS tumors (2.2%), metastases of 
solid tumors (3.2%) and hematologic malignancies (2.9%) [3].
Infections are another well-established cause of CVTs. Developed countries have shown a 
decline in infection related CVTs, but in developing countries at ~18% it remains a prevalent 
cause [36]. In ISCVT infection accounted for 8.2% of adults [37]. Locations of the parame-
ningeal infections were in the ear, sinus, mouth, face and neck. Cavernous sinus thrombo-
sis specifically is overwhelming caused by skin infections of the face and/or nasal sinuses, 
where the venous drainage flows directly into the cavernous sinus. Another syndrome, called 
Lemierre’s syndrome, results from oropharyngeal infection leading to thrombosis of the 
internal jugular vein which may back propagate causing extensive CVT. Further, the local-
ized inflammation may also invade the internal carotid arteries (ICA) as they pass through the 
oropharynx, thereby leading to arterial strokes.
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In children, infection was the most common cause of CVT. Among neonates, infection 
occurred in 84% of all patients [10]. In patients older than 1 month, the majority of case etiolo-
gies shifted towards chronic medical conditions, including connective tissue disorders (23%), 
hematologic diseases (20%) and cancers (13%) [10].
5. Clinical presentation
CVT is a diagnosis that is often delayed given its variable presentation. ISCVT patients 
were diagnosed a median of 7 days after symptom-onset, most of whom diagnosed were 
diagnosed between 48 hours and 30 days from symptom-onset (56%,). This time-period was 
followed by: acute <48 hours (37%), and chronically >30 days (7%). Across all time-periods, 
the median delay from symptom-onset until admission was 4 days [3, 38, 39]. Interestingly, 
delay in diagnosis was associated with increased risk of visual deficits [39]. Men and patients 
with isolated elevated ICP were diagnosed later. It is helpful to consider the two primary 
mechanisms that cause neurologic dysfunction: (1) increased intracranial pressure (ICP) and 
(2) hypoperfusion.
The increased intracranial pressure is due to poor venous outflow effectively leading to 
increased cerebral venous resistance and decreased CSF drainage, thus increasing ICP [40]. 
The increased ICP generally results in three manifestations: headache, diplopia and papill-
edema. In ISCVT, almost 90% of patients examined had headache as a presenting symptom. 
The headaches were generally described as diffuse progressing over days to weeks, with 
thunderclap headache being the rare presentation [3, 41]. The authors recommended a higher 
index of suspicion for high risk patients (women of childbearing age especially on OCPs in 
isolation or in combination with smoking) who have a new and/or atypical headache not 
responsive to over the counter analgesics [41]. Patients presenting with isolated headaches 
had a favorable prognosis in one study [42]. Patients not presenting with headache in the 
ISCVT cohort were older men and were more likely to have cancer [43]. The mortality was 
higher in that group, but there was no statistically significant difference when adjusting for 
confounders in the data [42].
In addition, the increased ICP may also lead to papilledema. The clinical symptoms can be 
transient visual obscurations, transient vision loss, peripheral vision loss and pulsatile tin-
nitus. Nausea and vomiting are also common. The diplopia is often caused by compression 
of one or both abducens nerves leading to horizontal diplopia. More directly, cavernous sinus 
thrombosis may lead to diplopia via localized involvement with the oculomotor and abdu-
cens nerves as they pass through the cavernous sinus. Class I, level C evidence in guidelines 
suggests cerebral venous imaging in patients with clinical symptoms of increased intracranial 
pressure [38].
The other primary mechanism is venous infarction as related to a combination of hypoperfu-
sion, ischemia and/or hemorrhagic injury. In such instances, focal neurologic syndromes are 
encountered in the patterns previously described in the previous “Anatomy and Associated 
Clinical Syndromes” section. Should hemorrhagic and/or ischemic strokes develop, focal neu-
rologic deficits such as aphasia or hemiparesis can be seen. Patients can present with acute 
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psychosis, typically in combination with other signs and symptoms, but rarely as the sole 
manifestation. Seizures are also very common, as there is often a disturbed blood–brain bar-
rier with edema development in the setting of viable cortical neurons and supporting cells. 
Seizures can be focal, unilateral or bilateral, and can also secondarily generalize. In ISCVT 
seizures were present in 40% of subjects [3].
6. Diagnostic evaluation
After a thorough history and physical examination, the most useful diagnostic tool is imag-
ing. As with most patients, the initial scan will be a non-contrast computed tomography (CT) 
of the head. The purpose of these initial screening images is to evaluate for signs of ischemia, 
hemorrhage, a “filled” or hyperdense delta sign and/or other evidence of hyperdense venous 
sinuses. These are the radiographically important CT imaging findings seen in the setting of 
CVT. The non-contrast CT is estimated to be abnormal in 30% of individuals with CVT [1, 23, 
44–48]. ICH is the initial presentation in 30–40% of CVT patients [49, 50]. The filled delta sign 
is a triangular hyperdensity in the posterior portion of the superior sagittal sinus in the area 
of the confluence of the sinuses. A hyperdense dural sign, indicating CVT in a dural vein, is 
appreciated on approximately 1/3 CVT cases undergoing CT head [44, 45, 47]. Furthermore, 
the index of suspicion is raised higher if there is hemorrhage that is atypical in appearance, 
meaning that it is close to venous sinuses and/or crosses typical arterial vascular borders.
When patients present with focal neurologic deficits within an acute intervention window (up 
to 24 hours since last known well in certain circumstances), the recommendation of the authors 
is to perform an emergent CT angiogram (CTA) with delayed phase CT venogram (CTV) as 
part of the initial evaluation. These studies evaluate patients for large-vessel arterial occlusion, 
with the CTV performed primarily to evaluate for collateral flow in the setting of potential 
mechanical thrombectomy. However, an added benefit of the delayed phase CTV is that one 
is also able to evaluate for venous thrombus. Anecdotally, the authors have discovered CVT 
in the initial CT/CTA/CTV approach in patients with hemorrhagic strokes presenting acutely. 
A dedicated CTV evaluates the venous sinuses themselves, which would demonstrate throm-
bosis if present. Some suggest that CTV is more valuable in the subacute and chronic phases 
because it shows varying density of the thrombosis within the sinuses [38].
MRI is also helpful in the evaluation of CVT. In addition to ruling in or out other diagnoses 
on the differential, including brain tumors for example, it can provide helpful information 
for confirming CVT. Consistent with the non-contrast CT brain, the pattern and location of 
injury can be helpful if hemorrhage or ischemia is present. Parenchymal damage can mani-
fest as ischemia (restricted diffusion), edema and hemorrhage. Edema without hemorrhage 
is more easily detected on MRI versus CT brain (25% versus 8%) respectively [10, 44, 46, 
51–57]. Hemorrhage-specific MRI sequences are positive in up to 40% of CVT patients [44, 51, 
53, 57–60]. The pattern of parenchymal injury often provides clues to the venous structures 
involved. For example, simultaneous injury involving the frontal, parietal and occipital corti-
ces would correspond to a superior sagittal sinus thrombosis. Transverse and sigmoid sinuses 
result in temporal lobe injury. Deep structures are injured in thrombosis of the straight sinus 
Cerebral Venous Thrombosis: A Clinical Overview
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and/or vein of Galen. MRI T2 weighted sequences can provide insight into the venous sinuses 
themselves, with absent flow voids manifesting as T2 hypointensities. Such findings, can be 
suggestive of CVT especially with accompanying parenchymal changes discussed above. 
Although uncommon, hyperintense cortical veins on T2 sequences can be used to identify 
isolated cortical vein thrombosis [51, 61–68].
If CVT is clinically suspected, dedicated venous imaging is required, even if the initial plain 
brain CT brain or brain MRI were negative. As discussed, CTV can be used, however MRV is 
another option. MRV reveals loss of flow signal in the venous sinuses [69]. This can be espe-
cially helpful when combined with above modalities. In our practice, we use susceptibility 
weighted imaging on MRI to help augment diagnostic accuracy in combination with MRV.
DSA is indicated in patients with parenchymal changes (edema and/or hemorrhage) without 
conclusive venography on CTV or MRV. A 4-vessel DSA will help evaluate for possible arte-
rial etiologies to the observed parenchymal damage, however the late-phase contrast runoff 
can be used to examine the venous system. As another option, some authors suggest direct 
venography via micro-catherization of the internal jugular vein [70, 71]. Such a technique 
might be useful if an intervention is being considering.
From a serology standpoint, D-dimer has an excellent negative predictive value (99.6%), 
which is helpful in identifying patients with low probability of having CVT [72, 73]. In one 
prospective multicenter trial, D-dimer had a specificity of 91.2% and sensitivity of 97.1% [72]. 
There was a smaller study that found that the false negative rate was 10% in patients present-
ing with isolated headache [73]. Interestingly, there was a positive correlation with D-dimer 
level and extent of CVT, and negative correlation with duration of symptoms [72–77].
After the diagnosis is established it is important to identify the etiology. Recommended 
lab tests as per evidence-based guidelines in the acute setting include: complete blood 
count (CBC), complete metabolic panel (CMP), prothrombin time (PT) and activated partial 
thromboplastin time (aPTT). Hypercoagulable testing for protein C, protein S, antithrombin, 
anticardiolipin and antiphospholipid antibodies, prothrombin G20210A mutation and fac-
tor V Leiden [38, 78–82] are also valuable and should be considered early. In the setting of 
anticoagulation use, only antibody and genetic tests are possible. If infection is considered, 
blood cultures should be attained. In certain populations, it is not unreasonable to perform a 
malignancy screen with CT chest, abdomen and pelvis ±testicular ultrasound.
7. Treatment
Patients who are suspected of having CVT benefit from evaluation by a vascular neurologist 
and being admitted to a stroke unit [83, 84]. Once a CVT is confirmed, the goal of therapy is 
to initiate anticoagulation quickly with the goal of preventing thrombus propagation. The 
data for CVT is certainly not as robust as many other areas of stroke therapy with a total of 12 
published studies to date [3, 40, 49, 55, 85–94], with only 2 randomized-prospective-controlled 
trials [40, 85].
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The first study evaluating CVT treatment was published in Lancet [85]. This double-blind 
placebo-controlled trial aimed to shed light on the ongoing treatment controversies at that 
time in clinical practice [85]. The prevailing thought that anticoagulation frequently caused 
ICH. The study included 20 patients with aseptic CVT randomized to anticoagulation versus 
placebo. The anticoagulation arm consisted of a heparin bolus of 3000 international units 
(IU) followed by continuous infusion adjusted to goal PTT 2× the pretreatment value. The 
primary outcome measure was a CVT severity scale which considered headache, focal signs, 
seizures and level of consciousness. The secondary outcome was ICH. The study was pow-
ered to evaluated 60 patients; however, enrollment was stopped at 20 given the clear benefit 
of treatment with anticoagulation at the interval analysis. The heparin group showed statisti-
cally significant benefit (Mann-Whitney U test p < 0.05) comparing the primary outcome at 
day 3 and day 8 (p < 0.01). At 3 months 8 patients in the treatment arm had complete recovery 
and 2 had slight neurologic deficits. In the placebo group 1 patient had complete recovery, 6 
with neurologic deficits, and 3 patients were deceased. Notably, none of the treatment group 
patients developed ICH.
The larger of the two RCTs enrolled patients in the United Kingdom and Netherlands between 
7/1992 and 11/1996 [40]. The entire population included 59 patients who were confirmed to 
have CVT using MRI, MRV and/or angiography. These were adult patients (≥18 years old) 
with the major exclusion criteria including pregnancy, contraindications for heparin use, 
poor baseline prognosis, increased ICP requiring lumbar puncture (LP) or shunt. The two 
arms evaluated nadroparin (190 units/kg/24 hours) versus placebo. After 21 days the blinding 
was broken and patients in the treatment arm got 10 weeks of warfarin with an international 
normalized ration (INR) goal 2.5–3.5. The placebo group did not receive anticoagulation or 
have sham bloodwork. The primary outcome was the Barthel index (BI) at 21 days expressed 
as a percentage, with a poor outcome defined as BI >15. Notable baseline characteristics for 
enrolled patients included: a mean age of 36.9 years old (range 18–80), 85% female, delay to 
randomization 10.6 days, 95% with recent headache, 47% with seizures, 96.6% with a focal 
neurologic deficit and 49% with cerebral hemorrhage. After 3 weeks, the anticoagulation arm 
was shown to have poor outcome in 20% of patients versus 24% for placebo, which was not 
statistically significant. At 12 weeks a secondary evaluation of poor outcome was performed, 
defined as death or Oxford Handicap Score ≥ 3. Poor outcomes were shown in 13% of antico-
agulation group versus 21% of placebo group (risk difference 27% [−26–12%]) which was also 
not statistically significant. The primary take home point per the study investigators was that 
there was no new hemorrhage, this, even in the treatment group. As such, anticoagulation 
was deemed safe despite the presence of cerebral hemorrhage at the time of CVT presen-
tation. Although, the presence of cerebral hemorrhage at presentation was associated with 
mortality in the study. Notably, the lack of increased frequency of new ICH while receiving 
anticoagulation therapy is in agreement with other studies that demonstrating low hemor-
rhage rates after initiation of anticoagulation in the setting of CVT [85, 88].
In the setting of CVT, a non-randomized prospective cohort study compared the efficacy of 
unfractionated heparin (UFH) versus low molecular weight heparin (LMWH); 302 patients 
received UFH versus 119 patients received LMWH [95]. The primary endpoint was functional 
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independence at 6 months defined as modified Rankin score < 3. More patients in the LMWH 
arm were functionally independent after 6 months (92% versus 84%). This was statistically 
significant in univariate (OR 2.1 [1.0–4.2], p 0.04) and multivariate adjusted analysis (OR 2.4 
[1.0–5.7], p 0.04). There was no statistically significant difference in the main secondary end-
points, which included: complete recovery—measured as a modified Rankin Scale (mRS) 0–1, 
mortality, and new intracranial hemorrhage. Another study, performed in India, further sub-
stantiated the claim that LMWH has a benefit in hospital mortality as compared to UFH [96].
The most recent guideline recommendations are that patients with confirmed CVT should 
be given anticoagulation initially with either UFH or LMWH followed by warfarin offered as 
class IIa and level of evidence B [40, 85, 88, 92, 97, 98]. There are no large studies evaluating the 
efficacy of direct acting oral anticoagulants (DOACs) in CVT, as such, warfarin is generally 
preferred. However, there are occasions when the authors consider and do initiate DOACs/
NOACs, including patient preference and in the setting of warfarin interactions with other 
medications [99, 100].
7.1. Rescue therapies: endovascular intervention
Endovascular intervention is considered when there is clinical deterioration despite antico-
agulation [101–110]. These patients often have clot propagation leading to further infarction 
or hemorrhagic injury, worsening ICP elevated due to poor venous outflow, or a combination 
of these factors. One of the approaches for so-called rescue therapy in CVT is delivery of intra-
sinus thrombolytics. At present, there are no randomized, double-blinded, placebo-controlled 
trials evaluating the efficacy of intrasinus thrombolysis. This procedure is rarely performed 
and would be best referred to a large academic center with robust interventional neuroradio-
logic experience [103].
A systematic review evaluated at total of 26 patients undergoing intrasinus thrombolysis 
including 80.8% with superior sagittal sinus thrombosis and 19.2% with deep sinus involve-
ment [104]. Urokinases were used in 73.1% of the cases, followed by streptokinase (7.7%), 
with the remainder utilizing recombinant tissue plasminogen activator (rTPA). Radiographic 
success of recanalization was attained in 61.5% patients, with 88% attaining a mRS 0–2 at last 
available follow up. Complications included ICH in 11.5% of cases, extracranial hemorrhages 
in 19.2%, and 2 deaths (7.7%).
Another 29 patients were evaluated in a series conducted from 4/2013 to 4/2016 all of whom 
were treated with in-situ tPA with the tPA delivered directly into the venous sinus via micro-
catheter [105]. The radiographic success of recanalization was 100% in this series, of which 
82.8% had favorable outcome (mRS 0–1), 10.3% mRS of 2, and 3.4% (1 patient) died.
Another prospective case series evaluated patients with CVT who underwent intrasinus 
thrombolysis among patients with altered mental status, coma, straight sinus thrombosis, or 
large space occupying lesions [106]. The population included 20 patients (80% women, mean 
age 32 years old) who received infused urokinase via internal jugular catheter. Clinically 60% 
of patients were comatose and 70% had hemorrhage prior to treatment. In 75% of patients the 
thrombolysis was coupled with mechanical thrombus disruption or removal. Post intervention 
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the mortality rate was 30% (6 patients), 5 of whom had large hemispheric infarcts and edema 
prior to intervention. Ultimately an mRS of 0–2 was achieved in 60% of cases.
Another study evaluated 37 CVT patients between 1/2007 and 12/2009 who underwent intra-
sinus urokinase infusion thrombolysis using a microcatheter [107]. At 6-month follow up, 
radiographic canalization was obtained in 97% of patients, with functional outcome rates of 
mRS 0–1 (75.8%), mRS 2 (18.2%), mRS 4 (3.0%), and a 3.0% mortality rate (mRS 6).
Another rescue therapy utilized is mechanical thrombectomy. One systematic review evalu-
ated patients from 42 studies treated between 1/1995 and 2/2014 undergoing mechanical 
thrombectomy with or without intrasinus thrombolysis [108]. The review included a total 
of 185 patients with CVT, 62% of whom had ICH prior to intervention. Clinically 47% were 
either stuporous or comatose. The most commonly used interventional device for mechanical 
thrombectomy was an AngioJet, used in 40% of the cases, although it was associated with a 
lower complete recanalization rate (OR 0.2 [0.09–0.4]) and lower chance of mRS 0–2 (OR 0.5 
[0.2–1.0]) as compared with other therapies. A total 71% of these patients also underwent 
intrasinus thrombolysis. A mRS 0–2 was observed in 84% of patients and the mortality rate 
was 12%. At least partial recanalization was obtained in 95% of cases. The major complications 
included new or increased ICH in approximately 10% of the cases.
Another systematic review in BMJ evaluated 17 studies totaling 235 patients [109]. Intrasinus 
thrombolysis was used in 87.6% of patients. Radiographically complete revascularization was 
achieved in 69% of patients, with a mortality rate of 14.3%, 1.2% recurrent CVT rate, and a 
new or worsening ICH rate of 8.7%.
Another review evaluated CVT patients undergoing mechanical thrombectomy between 1990 
and 2012 [110]. A total of 64 patients underwent mechanical thrombectomy with different 
techniques including AngioJet (46.9%), Penumbra (4.7%), Fogarty catheter (1.6%), microsnare 
(3.1%), balloon venoplasty without stenting (18.7%), balloon venoplasty with stenting (4.7%), 
and a combination approach (18.7%). The mortality rate in this review was 16.1%. The mor-
bidity data showed mRS 0–2 (62.5%), mRS 3–5 (10.9%) and 12.5% were unreported.
7.2. Decompressive surgery
Patients with CVT are at risk of herniation syndromes due to multiple factors as related to 
mass effect. Herniation is a major cause of death in CVT, thus decompressive surgery is an 
important option in the treatment armamentarium. Herniation is generally due to large isch-
emic regions and/or large hematomas. One study evaluated the safety and efficacy of decom-
pressive surgery in a retrospective fashion by evaluating a registry of acute CVT patients 
[111]. A total of 69 patients were included in the study, 45 underwent decompressive cra-
niectomy, 7 underwent hematoma evacuation, and 17 received both therapies. The primary 
outcome was mRS at last follow-up analyzed in dichotomously (favorable mRS 0–2 versus 
unfavorable mRS 5–6). In median 12-month follow-up 17.4% had an unfavorable outcome. 
This also resulted in favorable functional outcomes in the secondary analysis demonstrat-
ing 37.7% with near complete recovery (mRS 0–1), 56.5% (mRS 0–2), 5.8% (mRS 4–5), and a 
15.9% mortality rate. As consistent with decompressive surgery in arterial ischemic stroke, it 
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is important to treat early, before patients decline into a comatose state. As demonstrated in 
the just described study, patients who were comatose were less likely to be independent mRS 
<2 than non-comatose patients (45% versus 84%, p-value 0.003).
7.3. Seizures
Seizures are very common at presentation among patients with CVT. One prospective obser-
vational study found seizures in 39.3% of CVT patients and 6.9% of patients had early seizures 
(within 2 weeks) [112]. Factors associated with seizures at presentation were supratentorial 
lesions, cortical vein thrombosis, sagittal sinus thrombosis, and puerperal CVT. Beyond sei-
zures at presentation, supratentorial lesions were also a predicator of early seizures. Patients 
who suffer a seizure at presentation, or in the early phase of CVT, should be treated with 
antiepileptics for prevention of further seizures, this, whether a parenchymal lesion is seen on 
imaging or not. Currently, it is not recommended to treat prophylactically in the absence of 
a seizure. However, patients with acute and florid CVT are quite prone to seizures, with the 
occurrence of even a single seizure potentially negatively impacting outcome. Hence, in such 
situations, initiating a short course of antiepileptic drugs is highly reasonable and should be 
considered. As a general guideline, the authors treat for 14 days when there is one isolated 
seizure at presentation or early in the course. If there is more than one seizure the authors 
will treat for 3–6 months and discontinue therapy if no additional seizures occurred outside 
the acute phase. One observational study provides some evidence supporting prophylactic 
AED treatment in the setting of supratentorial lesions in the absence of seizures reporting 1 
seizures in 148 patients treated with AEDs versus 25 in 47 patients without AEDs (OR 0.006 
[0.001–0.05]) [112].
7.4. Increased intracranial pressure
Obstruction of the venous sinuses will increase the intracranial pressure (ICP). Common 
symptoms include headache and papilledema. Patients who experience papilledema and 
visual disturbances need to be monitored closely for further decompensation of visual fields. 
In the event symptoms, acetazolamide can be initiated with similar dosing to idiopathic 
intracranial hypertension (IIH). The authors generally initiate therapy at 500 mg twice a day 
and up-titrate as needed for therapeutic efficacy. If additional supplementation is needed, 
or for prophylaxis, the authors generally use topiramate titrated to efficacy with maximum 
daily dose being 200 mg total in 2 equally-divided doses. Abortive headache management 
approaches start conservatively with acetaminophen followed by ibuprofen or other NSAIDs 
(i.e., ketorolac), then tramadol, opioids and lastly migraine cocktails.
The treatment of emergency vision loss requires rapid, but careful consideration. Possible 
etiologies include elevated ICP or retinal ischemia. Treatment options for elevated ICP in 
a correlated disease, idiopathic intracranial hypertension (IIH), include optic nerve sheath 
fenestration and ventriculoperitoneal shunt procedures. The issue unique to CVT is the fact 
that the underlying visual loss etiology is due to venous obstruction and/or congestion. Thus, 
there are circumstances where it would be beneficial to evaluate if the venous outflow is 
completely obstructed, thereby leading to retinal flow stasis and subsequent retinal ischemia. 
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In that case, the authors would advocate serious consideration of interventional clot extrac-
tion to restore venous flow and thus decrease ICP. This is based on opinion. Guidelines do 
cite LP, optic nerve decompression, and shunts as possible treatment options but do not 
delineate timing of these procedures in relation to rescue revascularization therapy. Deep 
venous system or cavernous sinus thromboses progressing to occlude retinal outflow tracts 
are particularly worrisome. These etiologies can cause permanent blindness and should be 
considered in the setting of acute vision loss. An urgent ophthalmological evaluation in such 
situations is highly warranted.
Lumbar punctures (LP) are not required in the diagnostic evaluation of CVT. However, if ICP 
measurement is necessary, it is safe to do an LP even in the acute phase [113]. The expected 
CSF chemistry profile is a pleocytosis (50%) and an elevated protein (35%) [3], but these CSF 
abnormalities are not specific to a CVT diagnosis. LP is generally used to measure ICP and/or 
to evaluate for other underlying etiologies (e.g., infection).
7.5. Special considerations
7.5.1. Pregnancy
The ISCVT cohort evaluated 119 women for a median follow up time of 14 months with a 
total of 82 pregnancies occurring among 47 women [114]. Recurrent venous thrombotic event 
(VTE) occurred only in 3 of the 82 pregnancies (1 of which was recurrent CVT). A majority, 
83%, of the total cohort received prophylactic DVT treatment during at least one trimester, 
including 2 of the 3 patients that had a VTE event. The outcomes of the pregnancies were as 
follows: 51 full-term newborns, 9 preterm births, 2 stillbirths, and 20 abortions (14 spontane-
ous). CVT patients who are pregnant or become pregnant are recommended to continue anti-
coagulation. Warfarin is not recommended because of its teratogenic effects. In these cases, 
the authors recommend using enoxaparin throughout the duration of pregnancy. LMWH is 
preferred over UFH. Guidelines also suggest continuation with either LMWH or warfarin 6 
weeks postpartum [38]. If this becomes problematic, then the authors would consider the use 
of DOACs with the preference being apixaban in patients with normal renal function.
In women of childbearing age, especially those who had a CVT due to OCP use, it is rec-
ommended that the women use contraceptive methods without hormonal components. 
Generally, this is intrauterine device (IUD) therapy. Sometimes emergency contraception is 
indicated [115]. CVT does not preclude one from getting pregnant in the future but should be 
monitored closely in a high-risk pregnancy clinic as dictated by an obstetrician. Collaboration 
between the neurologist and obstetrician is recommended. The decision for prophylactic ther-
apy during subsequent pregnancies should be done on an individual patient basis. However, 
the authors generally recommend daily prophylaxis with enoxaparin especially in the third 
trimester.
7.5.2. Infections
Analysis of the ISCVT cohort revealed that new ICH was more frequent in patients with 
infection as the etiology of their CVT [116]. The study compared infected versus noninfected 
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patients, with infected patients representing 9.4% of the cohort. New ICH occurred in 12.3% 
versus 5.3% (p-value 0.04) within similar rates of heparin use in each group. Notably, there 
was no difference in death or dependency between the two groups.
7.5.3. Steroids
A subset (24%) of patients in ISCVT received steroids in the acute CVT phase. Steroid use in 
the acute phase is not clinically beneficial. Hence, steroids are not used in the setting of CVT.
7.5.4. Pediatrics
The approach to children with CVT is similar to adults. However, because children often have 
an infectious component to their CVT, much of the diagnostic evaluation should also include 
evaluations for infection [117–119]. Patients beyond 28 days old are recommended for acute 
therapy with LMWH and they should continue anticoagulation for 3–6 months (warfarin) 
[38]. Neonates should be considered for anticoagulation on a case by case basis. In pediatric 
patients, one should have a lower threshold to evaluate with EEG.
8. Prognosis and long-term follow-up
Many studies demonstrate a CVT recurrence rate between 2 and 5% [3, 7, 120–122]. Other 
VTE was demonstrated in 4.3–8% of patients in those studies. The ISCVT recurrence rate 
for CVT was 1.5 per 100 person-years, or 2.2% [123]. In the ISCVT study, mortality was 8.3% 
at 16 months [3]. A majority of patients (79%) had complete recovery defined as mRS 0–1, 
10.4% with mRS 2–3, 2.2% with mRS 4–5. Bilateral lesions were associated with unfavorable 
outcomes (50% versus 11%, p 0.004) and death (42% versus 11%, p 0.025) [111]. A previous 
VTE was a predictor of recurrence but not secondary or unprovoked CVTs [122]. Recurrence 
tended to occur within a year of the first CVT [3]. CVT has lower mortality and morbidity in 
comparison to other stroke types [1, 2]. Factors associated with poor outcome were older age, 
malignancy, CNS infection, and ICH [1]. Gender was not associated with poor outcomes after 
adjustment [8]. Independent predictors of death in the ISCVT were reported to include coma, 
mentational disturbances, deep CVT, right hemispheric ICH, and posterior fossa lesions. 
Causes of death were either transtentorial herniation or diffuse edema [13]. In a national data-
base from 2000 to 2007 the mortality rate was 4.39%. The mortality predictors in this study 
were older age, ICH, hematologic disorders, systemic malignancy and CNS infection [124].
Prognostic information was evaluated in the ISCVT patient cohort. With a median follow-up 
of 16 months, 57.1% had a mRS of 0, signifying no symptoms, while 8.3% died. The multi-
variate analysis identified statistically significant predictors of death and disability to include 
age > 37 years (hazard ratio (HR) 2.0), male sex (HR 1.6), coma (HR 2.7), GCS <9 (HR 2.65) 
hemorrhage on admission CT scan (HR 1.9), thrombosis of the deep cerebral venous system 
(HR 2.9), central nervous system infection (HR 3.3), and cancer (HR 2.9) [125]. Another study 
looked at the predictors of CVT outcome in patients with ICH, this in the ISCVT cohort [49]. 
Ischemic Stroke of Brain34
Early ICH was defined as ICH present at time of CVT diagnosis. A logistic regression analysis 
was performed using mRS 3–6 as dependent variable. The patients with early CVT represented 
39% of the CVT population at month 6. The independent predictors of death or dependency 
at 6 months with early ICH in CVT included: older age (adjusted OR for 1-year increase in 
age, 1.05 [1.02–1.08], male gender (adjusted OR 3.25 [1.29–8.16]), deep CVT (adjusted OR 5.43 
[1.67–17.61], right lateral sinus CVT (adjusted OR 2.56 [1.03–6.40] and motor deficit (adjusted 
OR 2.94 [1.21–7.10] [49].
9. Conclusions
CVT is a less common, but highly treatable, cause of stroke accounting for 0.5–1% of all 
strokes with a preponderance to occur in women. Our goal was to provide clinicians with 
the knowledge to rapidly diagnose CVT with an emphasis on etiologies and treatments in an 
effort to produce optimal clinical outcomes. Clinicians must possess a working knowledge of 
the relevant anatomy and associated clinical syndromes, and be aware of the relevant clinical 
trials as described herein. Clinicians must consider CVT when evaluating patients suffering 
with acute neurological changes, particularly those with predisposing risk factors such as 
OCP use, smoking, and a postpartum state, among others.
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